LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy.
Kobe City Medical Center General Hospital, Kobe, Japan.
Akio
A
Oishi
Kobe City Medical Center General Hospital, Kobe, Japan.
Noriko
N
Miyamoto
Kobe City Medical Center General Hospital, Kobe, Japan.
Michiko
M
Mandai
Kobe University Graduate School of Medicine, Kobe, Japan.
Shigeru
S
Honda
Hyogo Prefectural Amagasaki Hospital, Amagasaki, Japan.
Toshiyuki
T
Matsuoka
Hyogo Prefectural Amagasaki Hospital, Amagasaki, Japan.
Hideyasu
H
Oh
Hyogo Prefectural Amagasaki Hospital, Amagasaki, Japan.
Mihori
M
Kita
Steel Memorial Hirohata Hospital, Himeji, Japan.
Tomoko
T
Nagai
Mitsubishi Kobe Hospital, Kobe, Japan.
Nobuhiro
N
Bessho
Mitsubishi Kobe Hospital, Kobe, Japan.
Mamoru
M
Uenishi
Kobe City Medical Center General Hospital, Kobe, Japan.
Yasuo
Y
Kurimoto
Kobe University Graduate School of Medicine, Kobe, Japan.
Akira
A
Negi
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015862:Choroid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D057915:Drug Substitution; D006801:Humans; D058449:Intravitreal Injections; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011127:Polyps / Q000188:drug therapy* / Q000503:physiopathology; D011166:Porphyrins / Q000627:therapeutic use*; D000069579:Ranibizumab; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000069579:Ranibizumab